Among SGLT2 inhibitors users, the mean age (± SD) was 65.1 ± 11.5 years, 64.8% were men, 10.7% had a history of heart failure, 15.3% had a history of chronic kidney disease, and 29.2% had a history of ASCVD. This evidence concerns the gene SLC5A2 and atherosclerosis.